Gabapentin

Drug Usage Statistics, United States, 2004 - 2014

Number of Prescriptions Over Time (2004 - 2014)

Rank of Top Drugs Over Time

"Rank" refers to the frequency that a given medication is prescribed within a calendar year compared to all other medications. A rank of "4" would indicate that the medication was the fourth most commonly prescribed medication.

Year Rank Change
2004 35 -
2005 36  1
2006 36 0
2007 38  2
2008 31  7
2009 24  7
Year Rank Change
2010 23  1
2011 24  1
2012 17  7
2013 14  3
2014 12  2

Patient Out-Of-Pocket Cost Over Time (2004 - 2014)

"Out-of-pocket" cost refers to the payment made by the patient (either cash price or the copay amount). This value does not include reimbursement from a third party payer (eg, Medicare or private insurance) and does not represent the total drug cost.

Usage Statistics of Related Drugs

Drug Name Total Prescriptions (2014)
Gabapentin (this drug) 39,361,473
Lamotrigine 12,705,157
Divalproex Sodium 7,299,035
Phenytoin 4,310,314
Oxcarbazepine 4,148,661
Primidone 972,817

Drug Synonyms

Drug synonyms are used during the sanitation and standardization process of "cleaning" the original data source (MEPS). Occassionally, brand names may be listed below that are no longer on the market or are very infrequently used.

Brand Name Synonyms
  • Gralise
  • Neurontin
Generic Drug Synonyms and Salts
  • Gabapentin

FDA Approval Information

Established Pharmacologic Class (EPC): Anti-epileptic Agent
Initial FDA approval date: 12/30/1993
First FDA applicant: Pfizer Pharmaceuticals Ltd
First dosage form: Capsule (oral)

Prescription data source: Medical Expenditure Panel Survey (MEPS) 2004-2014. Agency for Healthcare Research and Quality (AHRQ), Rockville, MD. ClinCalc DrugStats Database version 17.0. Read more about the ClinCalc DrugStats database.

Search

Related Links

Follow Us!

New and Popular

Loading...

Open Menu

Cite This Page

Show AMA citation

Which of these drugs causes acute kidney injury? The Top 250 Drugs by ClinCalc Academy
©2017 - ClinCalc LLC. All rights reserved.
Disclaimer - Privacy Policy - Contact Us
Updated Mar 4, 2017
Back to Top
Top